The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The rapid rise of the SARS-CoV-2 variant XFG this summer could make it the dominant strain by the start of the fall COVID season, but experts say current vaccines can likely handle the Omicron-based ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The pound rose to USD1.3450 late on Friday afternoon in London, compared to USD1.3412 at the equities close on Thursday. The euro traded at USD1.1666, higher against USD1.1631. Against the yen, the ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

In its new guidelines, the American Heart Association says not all ultraprocessed foods are so bad — such as whole grain breads, low-sugar yogurts, tomato sauces, and nut or bean-based spreads. The ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...